Your English writing platform
Discover LudwigExact(1)
With the increasing life expectancy of patients with cystic fibrosis (CF), prevalence of late complications such as CF-related bone disease (CFBD) has increased.
Similar(59)
Additional studies of osteoporosis in CF report a prevalence of osteopenia ranging from 24 58% and a prevalence of osteoporosis ranging from 4 76% [ 7- 12].
In patients with CF, an increasing prevalence of A. xylosoxidans isolates has recently been reported [ 24– 28], but the clinical significance of A. xylosoxidans infection is still unclear.
Thus, despite being consistent with other studies [ 8- 10] as regards the general trends in the distribution of lineage-specific exons, our study provides evidence that lineage-specific loss of alternative exons and sites is an important factor in the evolution of alternative splicing (cf. the prevalence of intron loss over intron gain in mammals [ 35]).
Since 1990, an increasing number of studies have reported the recovery of NTM from the respiratory tract of patients with CF at a prevalence of 2%28%% (2 – 13 ); higher prevelances have been reported in the United States (14 ) than in Europe (4, 11 ).
In CF-bronchiectatic patients, prevalence of NTM varies from 5%to20%0% through different studies [ 35, 36].
Is the prevalence of CF mutations in the general population the same as that predicted from their frequency in CF patients?
Patients with CF have a GER prevalence of approximately 50%126.
The prevalence of CF varies and depends on the geographical location [ 1, 2].
One of the major issues in the control of bacterial infections in CF is the rising prevalence of multiresistant bacteria.
Two studies reported the prevalence of CF, 7.3% and 40%, and five studies described the prevalence of STS in a range from 21to44%4%.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com